Trial
NCT05348915
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Inclacumab
Why stopped
Sponsor decision to terminate study based on results of parent study GBT2104-131.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-17